Phase III Randomized Study of Chimeric Anti-GC2 in high risk neuroblastoma following myeloablative therapy and autologous stem cell rescue (Protocol - ANBL0032) (Brain)

ID Number 80-0066-00037

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)


This is a group-wide phase III Children’s Oncology Group study designed to determine if treatment with monoclonal antibody therapy, plus cytokines and 13-Cis-Retinoic Acid improves that outcome for children with high risk neuroblastoma, when compared to the standard treatment with 13-Cis-Retinoic Acid alone.

Contact Information
Nita Narayan
(212) 241-4142

Recruiting Patients: Yes